The Molecular Biology of Myeloma

David S. Siegel, MD, PhD
Video Categories: Targeted Therapies

Dr. David S. Siegel discusses the importance of understanding the molecular biology of myeloma. Physicians can now look at and offer alternative treatments to patients that they identify will most likely do poorly with traditional treatment. He believes this area will develop quickly over the next 2 to 5 years.
January 13, 2015

Benefits of Breast Cancer Index

Dr Stephen C. Malamud and Dr Susan K. Boolbol consider the clinical utility of the Breast Cancer IndexSM (BCI) as a test that separates those patients who are more likely to benefit from those who are unlikely to benefit from extended endocrine therapy.

January 30, 2014

Selecting the Appropriate Test for Individual Patients and Tumors

In this next segment, Dr Agarwala discusses when and how molecular tests should be utilized.